# US 2025/0154170 A1 · Fused pyrimidines as kras inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154170 A1
- Document ID: US20250154170A1
- Status: Published application
- Kind: A1
- Application number: 18/836,180
- Filed: 2023-02-09
- Published: 2025-05-15
- Earliest claimed: 2022-02-10
- Applicants: Bayer Aktiengesellschaft
- Inventors: Daniel Hillebrand O'DONOVAN; Wolfgang SCHWEDE; Jeremie Xavier G MORTIER; Volker SCHULZE; Sebastian ESSIG; Lisa CANDISH; Franziska SIEGEL; Lukas Patrik BRAUN; Gary Norbert HERMANN; Benjamin BADER; Yung-Ning CHANG; Roman HILLIG
- Web page: https://patentgrep.com/patent/US20250154170A1

## CPC

- C07D 513/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 31/52: Purines, e.g. adenine
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 473/18: one oxygen and one nitrogen atom, e.g. guanine
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention covers fused pyrimidine compounds of general formula (I): in which R1, R2, R3, R4, X, Y and Z are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant KRAS signaling, as a sole agent or in combination with other active ingredients.

## Claims

### Claim 1

A compound of general formula (I)
in which:
X is selected from the group consisting of ═N—, —NH—, —N(CH3)—, —CH═, —C(CH3)═ and —S—;
Y is selected from the group consisting of ═N—, —NH—, —N(CH3)—, —CH═, —C(CH3)═ and —S—,
with the condition, that X and Y are not simultaneous —CH═ or simultaneous —S—;
It is understood that the fragment —X═C(—Z)═Y— in general formula (I) has the meaning of either —X—C(—Z)═Y— or —X═C(—Z)—Y—;
Z is selected from the group consisting of —NH—, —N(CH3)—, —CH2—, —CH(CH3)—, —CH(OH)— and —O—;
R1 is selected from the group consisting of
R2 is selected from the group consisting of
R3 is selected from the group consisting of H, F, Cl, and —CH3;
R4 is selected from the group consisting of H, F, Cl, —CH3, and —C≡CH;
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

### Claim 2 (depends on 1)

The compound according to claim 1 which is selected from the group consisting of:
4-{[7-(3,8-diazabicyclo[3.2.1]octan-3-yl)-5-(tetrahydro-1H-pyrrolizin-7a(5H)-ylmethoxy)[1,3]thiazolo[5,4-d]pyrimidin-2-yl]oxy}-2-naphthol,
4-{[7-(3,8-diazabicyclo[3.2.1]octan-3-yl)-5-(tetrahydro-1H-pyrrolizin-7a(5H)-ylmethoxy)[1,3]thiazolo[5,4-d]pyrimidin-2-yl]oxy}-5-ethynyl-2-naphthol,
4-({7-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-5-[(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy][1,3]thiazolo[5,4-d]pyrimidin-2-yl}oxy)-5-fluoronaphthalen-2-ol,
4-({7-(3,8-diazabicyclo[3.2.1]octan-3-yl)-5-[(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy][1,3]thiazolo[5,4-d]pyrimidin-2-yl}oxy)-5-methylnaphthalen-2-ol,
4-({7-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-5-[(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy][1,3]thiazolo[5,4-d]pyrimidin-2-yl}oxy)-5-ethynyl-6-fluoronaphthalen-2-ol,
4-{[7-(3,8-diazabicyclo[3.2.1]octan-3-yl)-5-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}[1,3]thiazolo[5,4-d]pyrimidin-2-yl]oxy}-5-ethynyl-6-fluoronaphthalen-2-ol,
4-({7-(3,8-diazabicyclo[3.2.1]octan-3-yl)-5-[(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy][1,3]thiazolo[5,4-d]pyrimidin-2-yl}amino)naphthalen-2-ol,
4-({6-(3,8-diazabicyclo[3.2.1]octan-3-yl)-9-methyl-2-[(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy]-9H-purin-8-yl}oxy)-5-fluoronaphthalen-2-ol,
4-({6-(3,8-diazabicyclo[3.2.1]octan-3-yl)-9-methyl-2-[(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy]-9H-purin-8-yl}oxy)naphthalen-2-ol,
4-({6-(3,8-diazabicyclo[3.2.1]octan-3-yl)-2-[(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy]-9H-purin-8-yl}oxy)naphthalen-2-ol,
4-({6-(3,8-diazabicyclo[3.2.1]octan-3-yl)-2-[(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy]-9H-purin-8-yl}oxy)-5-fluoronaphthalen-2-ol,
5-ethynyl-6-fluoro-4-{[5-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}-7-(3-oxa-7,9-diazabicyclo[3.3.1]nonan-7-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-yl]oxy}naphthalen-2-ol,
5-ethynyl-6-fluoro-4-({7-(3-oxa-7,9-diazabicyclo[3.3.1]nonan-7-yl)-5-[(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy][1,3]thiazolo[5,4-d]pyrimidin-2-yl}oxy)naphthalen-2-ol,
4-({7-(3,8-diazabicyclo[3.2.1]octan-3-yl)-5-[(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy][1,3]thiazolo[5,4-d]pyrimidin-2-yl}methyl)-5-fluoronaphthalen-2-ol,
5-Chlor-4-{[7-(3,8-diazabicyclo[3.2.1]octan-3-yl)-5-(tetrahydro-1H-pyrrolizin-7a(5H)-ylmethoxy)[1,3]thiazolo[5,4-d]pyrimidin-2-yl]oxy}-2-naphthol,
4-[(7-[(1R*,5R*)-3,6-diazabicyclo[3.2.2]nonan-3-yl]-5-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}[1,3]thiazolo[5,4-d]pyrimidin-2-yl)oxy]-5-ethynyl-6-fluoronaphthalen-2-ol,
4-{[7-(3,8-diazabicyclo[3.2.1]octan-3-yl)-5-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}[1,3]thiazolo[5,4-d]pyrimidin-2-yl]oxy}-5-ethenyl-6-fluoronaphthalen-2-ol,
4-({6-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-methyl-2-[(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy]-7H-purin-8-yl}oxy)naphthalen-2-ol,
5-ethynyl-6-fluoro-4-{[5-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}-7-(3-oxa-7,9-diazabicyclo[3.3.1]nonan-7-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-yl]oxy}naphthalen-2-ol,
4-[(7-[(1R*,5R*)-3,6-diazabicyclo[3.2.2]nonan-3-yl]-5-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}[1,3]thiazolo[5,4-d]pyrimidin-2-yl)oxy]-5-ethynyl-6-fluoronaphthalen-2-ol,
4-[(7-[(1S*,5S*)-3,6-diazabicyclo[3.2.2]nonan-3-yl]-5-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}[1,3]thiazolo[5,4-d]pyrimidin-2-yl)oxy]-5-ethynyl-6-fluoronaphthalen-2-ol,
4-({6-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-methyl-2-[(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy]-7H-purin-8-yl}oxy)-5-ethynyl-6-fluoronaphthalen-2-ol
6-chloro-4-{[7-(3,8-diazabicyclo[3.2.1]octan-3-yl)-5-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}[1,3]thiazolo[5,4-d]pyrimidin-2-yl]oxy}-5-ethynylnaphthalen-2-ol
5-Ethynyl-6-fluoro-4-[(7-[(1R*,5R*)-6-fluoro-3,8-diazabicyclo[3.2.1]octan-3-yl]-5-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}[1,3]thiazolo[5,4-d]pyrimidin-2-yl)oxy]naphthalen-2-ol,
5-Ethynyl-6-fluoro-4-[(7-[(1R*,5R*)-6-fluoro-3,8-diazabicyclo[3.2.1]octan-3-yl]-5-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}[1,3]thiazolo[5,4-d]pyrimidin-2-yl)oxy]naphthalen-2-ol,
5-Ethynyl-6-fluoro-4-[(7-[(1R*,5R*)-6-fluoro-3,8-diazabicyclo[3.2.1]octan-3-yl]-5-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}[1,3]thiazolo[5,4-d]pyrimidin-2-yl)oxy]naphthalen-2-ol,
5-Ethynyl-6-fluoro-4-[(7-[(1R*,5R*)-6-fluoro-3,8-diazabicyclo[3.2.1]octan-3-yl]-5-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}[1,3]thiazolo[5,4-d]pyrimidin-2-yl)oxy]naphthalen-2-ol,
4-{[7-(3,8-diazabicyclo[3.2.1]octan-3-yl)-5-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}[1,3]thiazolo[5,4-d]pyrimidin-2-yl]amino}naphthalen-2-ol,
4-{[7-(3,8-diazabicyclo[3.2.1]octan-3-yl)-5-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}[1,3]thiazolo[5,4-d]pyrimidin-2-yl](methyl)amino}naphthalen-2-ol,
4-{[5-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}-7-(3-oxa-7,9-diazabicyclo[3.3.1]nonan-7-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-yl]amino}-2-naphthol,
4-{[7-(3,8-diazabicyclo[3.2.1]octan-3-yl)-5-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}[1,3]thiazolo[5,4-d]pyrimidin-2-yl](methyl)amino}-5-ethynylnaphthalen-2-ol, and
4-{[7-(3,8-diazabicyclo[3.2.1]octan-3-yl)-5-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}[1,3]thiazolo[5,4-d]pyrimidin-2-yl]methyl}-5-ethynyl-6-fluoronaphthalen-2-ol formic acid (1/1)
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

### Claim 3 (depends on 1)

The compound of general formula (I) according to claim 1 for use in the treatment of a disease.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising a compound of general formula (I) according to claim 1 and one or more pharmaceutically acceptable excipients.

### Claim 5 (depends on 1)

A pharmaceutical combination comprising:
one or more first active ingredients, in particular compounds of general formula (I) according to claim 1, and
one or more active ingredients selected from the group consisting of:
131I-chTNT, abarelix, abemaciclib, abiraterone, acalabrutinib, aclarubicin, adalimumab, ado-trastuzumab emtansine, afatinib, aflibercept, aldesleukin, alectinib, alemtuzumab, alendronic acid, alitretinoin, alpharadin, altretamine, amifostine, aminoglutethimide, hexyl aminolevulinate, amrubicin, amsacrine, anastrozole, ancestim, anethole dithiolethione, anetumab ravtansine, angiotensin II, antithrombin III, apalutamide, aprepitant, arcitumomab, arglabin, arsenic trioxide, asparaginase, atezolizumab, avelumab, axicabtagene ciloleucel, axitinib, azacitidine, basiliximab, belotecan, bendamustine, besilesomab, belinostat, bevacizumab, bexarotene, bicalutamide, bisantrene, bleomycin, blinatumomab, bortezomib, bosutinib, buserelin, brentuximab vedotin, brigatinib, busulfan, cabazitaxel, cabozantinib, calcitonine, calcium folinate, calcium levofolinate, capecitabine, capromab, carbamazepine carboplatin, carboquone, carfilzomib, carmofur, carmustine, catumaxomab, celecoxib, celmoleukin, cemiplimab, ceritinib, cetuximab, chlorambucil, chlormadinone, chlormethine, cidofovir, cinacalcet, cisplatin, cladribine, clodronic acid, clofarabine, cobimetinib, copanlisib, crisantaspase, crizotinib, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daratumumab, darbepoetin alfa, dabrafenib, darolutamide, dasatinib, daunorubicin, decitabine, degarelix, denileukin diftitox, denosumab, depreotide, deslorelin, dianhydrogalactitol, dexrazoxane, dibrospidium chloride, dianhydrogalactitol, diclofenac, dinutuximab, docetaxel, dolasetron, doxifluridine, doxorubicin, doxorubicin+estrone, dronabinol, durvalumab, eculizumab, edrecolomab, elliptinium acetate, elotuzumab, eltrombopag, enasidenib, endostatin, enocitabine, enzalutamide, epirubicin, epitiostanol, epoetin alfa, epoetin beta, epoetin zeta, eptaplatin, eribulin, erlotinib, esomeprazole, estradiol, estramustine, ethinylestradiol, etoposide, everolimus, exemestane, fadrozole, fentanyl, filgrastim, fluoxymesterone, floxuridine, fludarabine, fluorouracil, flutamide, folinic acid, formestane, fosaprepitant, fotemustine, fulvestrant, gadobutrol, gadoteridol, gadoteric acid meglumine, gadoversetamide, gadoxetic acid, gallium nitrate, ganirelix, gefitinib, gemcitabine, gemtuzumab, Glucarpidase, glutoxim, GM-CSF, goserelin, granisetron, granulocyte colony stimulating factor, histamine dihydrochloride, histrelin, hydroxycarbamide, I-125 seeds, lansoprazole, ibandronic acid, ibritumomab tiuxetan, ibrutinib, idarubicin, ifosfamide, imatinib, imiquimod, improsulfan, indisetron, incadronic acid, ingenol mebutate, inotuzumab ozogamicin, interferon alfa, interferon beta, interferon gamma, iobitridol, iobenguane (123I), iomeprol, ipilimumab, irinotecan, Itraconazole, ixabepilone, ixazomib, lanreotide, lansoprazole, lapatinib, Iasocholine, lenalidomide, lenvatinib, lenograstim, lentinan, letrozole, leuprorelin, levamisole, levonorgestrel, levothyroxine sodium, lisuride, lobaplatin, lomustine, lonidamine, lutetium Lu 177 dotatate, masoprocol, medroxyprogesterone, megestrol, melarsoprol, melphalan, mepitiostane, mercaptopurine, mesna, methadone, methotrexate, methoxsalen, methylaminolevulinate, methylprednisolone, methyltestosterone, metirosine, midostaurin, mifamurtide, miltefosine, miriplatin, mitobronitol, mitoguazone, mitolactol, mitomycin, mitotane, mitoxantrone, mogamulizumab, molgramostim, mopidamol, morphine hydrochloride, morphine sulfate, mvasi, nabilone, nabiximols, nafarelin, naloxone+pentazocine, naltrexone, nartograstim, necitumumab, nedaplatin, nelarabine, neratinib, neridronic acid, netupitant/palonosetron, nivolumab, pentetreotide, nilotinib, nilutamide, nimorazole, nimotuzumab, nimustine, nintedanib, niraparib, nitracrine, nivolumab, obinutuzumab, octreotide, ofatumumab, olaparib, olaratumab, omacetaxine mepesuccinate, omeprazole, ondansetron, oprelvekin, orgotein, orilotimod, osimertinib, oxaliplatin, oxycodone, oxymetholone, ozogamicine, p53 gene therapy, paclitaxel, palbociclib, palifermin, palladium-103 seed, palonosetron, pamidronic acid, panitumumab, panobinostat, pantoprazole, pazopanib, pegaspargase, PEG-epoetin beta (methoxy PEG-epoetin beta), pembrolizumab, pegfilgrastim, peginterferon alfa-2b, pembrolizumab, pemetrexed, pentazocine, pentostatin, peplomycin, Perflubutane, perfosfamide, Pertuzumab, picibanil, pilocarpine, pirarubicin, pixantrone, plerixafor, plicamycin, poliglusam, polyestradiol phosphate, polyvinylpyrrolidone+sodium hyaluronate, polysaccharide-K, pomalidomide, ponatinib, porfimer sodium, pralatrexate, prednimustine, prednisone, procarbazine, procodazole, propranolol, quinagolide, rabeprazole, racotumomab, radium-223 chloride, radotinib, raloxifene, raltitrexed, ramosetron, ramucirumab, ranimustine, rasburicase, razoxane, refametinib, regorafenib, ribociclib, risedronic acid, rhenium-186 etidronate, rituximab, rolapitant, romidepsin, romiplostim, romurtide, rucaparib, samarium (153Sm) lexidronam, sargramostim, sarilumab, satumomab, secretin, siltuximab, sipuleucel-T, sizofiran, sobuzoxane, sodium glycididazole, sonidegib, sorafenib, stanozolol, streptozocin, sunitinib, talaporfin, talimogene laherparepvec, tamibarotene, tamoxifen, tapentadol, tasonermin, teceleukin, technetium (99mTc) nofetumomab merpentan, 99mTc-HYNIC-[Tyr3]-octreotide, tegafur, tegafur+gimeracil+oteracil, temoporfin, temozolomide, temsirolimus, teniposide, testosterone, tetrofosmin, thalidomide, thiotepa, thymalfasin, thyrotropin alfa, tioguanine, tisagenlecleucel, tislelizumab, tocilizumab, topotecan, toremifene, tositumomab, trabectedin, trametinib, tramadol, trastuzumab, trastuzumab emtansine, treosulfan, tretinoin, trifluridine+tipiracil, trilostane, triptorelin, trametinib, trofosfamide, thrombopoietin, tryptophan, ubenimex, valatinib, valrubicin, vandetanib, vapreotide, vemurafenib, vinblastine, vincristine, vindesine, vinflunine, vinorelbine, vismodegib, vorinostat, vorozole, yttrium-90 glass microspheres, zinostatin, zinostatin stimalamer, zoledronic acid, and zorubicin.

### Claim 6 (depends on 1)

A method of treating a disease, the method comprising use of a compound of general formula (I) according to claim 1.

### Claim 7 (depends on 1)

A method for preparing a medicament for treating a disease, the method comprising use of a compound of general formula (I) according to claim 1.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the disease is a neoplastic disorder, such as cancer or conditions with dysregulated immune responses or other disorders associated with aberrant KRAS signaling.

### Claim 9 (depends on 1)

A method for controlling neoplastic diseases in humans and animals by administering an anti-neoplastic effective amount of at least one compound as defined in claim 1.

### Claim 10 (depends on 1)

The method of claim 1, wherein the neoplastic disease is selected from the group consisting of lung adenocarcinoma, colorectal cancer, pancreatic cancer, cholangial cancer, ovarian cancer, and endometrial cancer.
